Quadrant Capital Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Quadrant Capital Group’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,280	Closed	-$11.7K	–	2735
2024 Q3	$11.7K	Buy	12,280 +9,062	+282%	+$10.3K	﹤0.01%	2097
2024 Q2	$3.14K	Sell	3,218 -3,035	-49%	-$3.33K	﹤0.01%	2403
2024 Q1	$9.88K	Buy	+6,253	New	+$7.55K	﹤0.01%	2110
2022 Q4	–	Sell	-1,046	Closed	-$1K	–	2734
2022 Q3	$1K	Buy	+1,046	New	+$1.92K	﹤0.01%	2457
2022 Q1	–	Sell	-2,466	Closed	-$9K	–	2473
2021 Q4	$9K	Sell	2,466 -754	-23%	-$3.43K	﹤0.01%	1654
2021 Q3	$17K	Buy	+3,220	New	+$14.4K	﹤0.01%	1315
2020 Q3	–	Sell	-131	Closed	-$1K	–	2149
2020 Q2	$1K	Buy	+131	New	+$823	﹤0.01%	2000

Other funds holding ADAP

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Quadrant Capital Group's ADAP Position: Q4 2024 in Review

Quadrant Capital Group sold out of Adaptimmune Therapeutics (ADAP) in Q4 2024, closing a stake of 12,280 shares — an estimated $11.7K sold.

Quadrant Capital Group first reported a position in ADAP in Q2 2020 and held it in 7 quarters. The position peaked at $17K in Q3 2021. 80 funds tracked by Wall St. Rank hold ADAP as of Q4 2024.

Quadrant Capital Group reported no remaining Adaptimmune Therapeutics position as of Q4 2024 after selling out during the quarter.
Quadrant Capital Group sold 12,280 Adaptimmune Therapeutics shares in Q4 2024, an estimated $11.7K.
Quadrant Capital Group first reported a position in Adaptimmune Therapeutics in Q2 2020 and held it in 7 quarters.
Quadrant Capital Group's Adaptimmune Therapeutics position peaked at $17K in Q3 2021.
80 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2024.

Based on Quadrant Capital Group's 13F filing for Q4 2024, filed 13 Feb 2025.